Concepedia

How should we assess the clinical and cost effectiveness of histology independent cancer drugs?

Sophie Cooper, Jacoline C. Bouvy, Lawrence Baker, F. Maignen, Páll Jónsson, Peter Clark, Stephen Palmer, Meindert Boysen, Nick Crabb

BMJ · 2020 · 21 citations · 6 references

DOI

Concepts

Abstract

Sophie Cooper, Jacoline Bouvy and colleagues discuss the challenges that histology independent cancer drugs will pose for NICE and the NHS

References

6

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

, , +16

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

Courtney Davis, Huseyin Naci, Evrim Gurpinar et al. · BMJ · 2017 · 605 citations · Full text

, , +15

Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe

Jacoline C. Bouvy, Claudine Sapède, Sarah Garner · Frontiers in Pharmacology · 2018 · 71 citations · Full text

, , +12

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs

Rick A. Vreman, Jacoline C. Bouvy, Lourens T. Bloem et al. · Clinical Pharmacology & Therapeutics · 2018 · 58 citations · Full text

, , +7

Registries in European post‐marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013

Jacoline C. Bouvy, Kevin Blake, Jim Slattery et al. · Pharmacoepidemiology and Drug Safety · 2017 · 36 citations · Full text

, , +16